ZANVASTRO

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
ZANVASTRO
Generic name
ZILGANERSEN
Manufacturer
Ionis Pharmaceuticals Inc.
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
af6ca330-46d3-4ed6-b2af-bd6db3133fd1
SPL ID
5b752db5-061f-8804-e063-6394a90aa4af
Version
3
Effective date
2026-09-14
Source export date
2026-11-13
Source partition
6
Source file
https://download.open.fda.gov/drug/label/drug-label-0006-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/a79c47b73cf1c0b9829667844daa083c5114cf268a1839f963bc5617e9060c4f/drug-label-0006-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:19:53

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS 5.1 Aseptic Meningitis If symptoms consistent with aseptic meningitis develop, diagnostic workup and treatment should be initiated according to the standard of care. Adverse reactions of aseptic meningitis (also called chemical meningitis or drug-induced aseptic meningitis) were reported in patients treated with ZANVASTRO during the double-blind and open-label periods of Study 1. One patient experienced a serious adverse reaction of aseptic meningitis during the double-blind treatment period of Study 1, which reoccurred in the open-label extension period and required dose interruption and pretreatment with intravenous dexamethasone prior to subsequent administration of ZANVASTRO. Despite corticosteroid premedication, CSF white blood cell (WBC) and protein increased with continued exposure but the patient remained asymptomatic and did not require discontinuation from treatment. In addition, nonserious adverse drug reactions of CSF WBC increased have also been reported with ZANVASTRO [see Adverse Reactions ( 6.1 )] .

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 4 matching rows.

adverse reactions

6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Aseptic Meningitis [see Warnings and Precautions ( 5.1 )] Most common adverse reactions (incidence >25% patients treated with ZANVASTRO and greater than control) were vomiting, back pain, cough, headache, and post-lumbar puncture syndrome. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Ionis Pharmaceuticals, Inc. at 1-833-644-6647 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of ZANVASTRO was evaluated in 53 pediatric and adult patients with Alexander disease in Study 1 [see Clinical Studies ( 14 )] . Thirty-eight patients received ZANVASTRO for 1 year, and 18 patients received ZANVASTRO for 2 years. The median exposure was 60 weeks in all groups. The most common adverse reactions during the Double-Blind Treatment Period (incidence >25% of patients treated with ZANVASTRO 50 mg and greater than control) were vomiting, back pain, cough, headache, and post-lumbar puncture syndrome. Table 3 includes the common adverse reactions that occurred in ≥10% of patients treated with ZANVASTRO and 10% greater than control. Table 3. Adverse Reactions in Patients with Alexander Disease that Occurred in ≥10% of Patients Treated with ZANVASTRO and 10% Greater than Control Adverse Reaction ZANVASTRO 50 mg (N=24) % Control (N=17) % Vomiting 50 29 Back pain 50 18 Cough 38 18 Headache 29 12 Post lumbar puncture syndrome 29 6 Arthralgia 25 6 Oropharyngeal pain 21 0 Dysphagia 17 6 Patients Less Than 2 Years of Age The adverse reactions of patients less than 2 years of age are expected to be similar to that of pediatric patients 2 years of age and older. Increased White Blood Cell Count in the CSF Pleocytosis (or increased white blood cell count in CSF) was observed in 7 (29%) patients treated with ZANVASTRO 50 mg following the administration of the first 2 to 4 doses, compared to 3 (18%) patients in the control group in the double-blind treatment period of the Main Study, and in an additional 6 patients treated with ZANVASTRO in the open-label extension period [see Warnings and Precautions ( 5.1 )] .

adverse reactions

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of ZANVASTRO was evaluated in 53 pediatric and adult patients with Alexander disease in Study 1 [see Clinical Studies ( 14 )] . Thirty-eight patients received ZANVASTRO for 1 year, and 18 patients received ZANVASTRO for 2 years. The median exposure was 60 weeks in all groups. The most common adverse reactions during the Double-Blind Treatment Period (incidence >25% of patients treated with ZANVASTRO 50 mg and greater than control) were vomiting, back pain, cough, headache, and post-lumbar puncture syndrome. Table 3 includes the common adverse reactions that occurred in ≥10% of patients treated with ZANVASTRO and 10% greater than control. Table 3. Adverse Reactions in Patients with Alexander Disease that Occurred in ≥10% of Patients Treated with ZANVASTRO and 10% Greater than Control Adverse Reaction ZANVASTRO 50 mg (N=24) % Control (N=17) % Vomiting 50 29 Back pain 50 18 Cough 38 18 Headache 29 12 Post lumbar puncture syndrome 29 6 Arthralgia 25 6 Oropharyngeal pain 21 0 Dysphagia 17 6 Patients Less Than 2 Years of Age The adverse reactions of patients less than 2 years of age are expected to be similar to that of pediatric patients 2 years of age and older. Increased White Blood Cell Count in the CSF Pleocytosis (or increased white blood cell count in CSF) was observed in 7 (29%) patients treated with ZANVASTRO 50 mg following the administration of the first 2 to 4 doses, compared to 3 (18%) patients in the control group in the double-blind treatment period of the Main Study, and in an additional 6 patients treated with ZANVASTRO in the open-label extension period [see Warnings and Precautions ( 5.1 )] .

adverse reactions table

<table width="50%" cellspacing="0" cellpadding="0"> <caption>Table 3. Adverse Reactions in Patients with Alexander Disease that Occurred in &#x2265;10% of Patients Treated with ZANVASTRO and 10% Greater than Control</caption> <col width="33.33%" align="left" valign="middle"/> <col width="33.33%" align="left" valign="middle"/> <col width="33.33%" align="left" valign="middle"/> <thead> <tr styleCode="First Last"> <td rowspan="2" align="left" styleCode="Lrule Rrule Toprule Botrule"> <content styleCode="bold">Adverse Reaction</content> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <content styleCode="bold">ZANVASTRO 50 mg (N=24) % </content> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <content styleCode="bold">Control (N=17) % </content> </td> </tr> </thead> <tfoot> <tr styleCode="First Last"> <td colspan="3" align="left" styleCode="Lrule Rrule Toprule Botrule"/> </tr> </tfoot> <tbody> <tr> <td align="left" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Vomiting</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>50</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>29</paragraph> </td> </tr> <tr> <td align="left" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Back pain</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>50</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>18</paragraph> </td> </tr> <tr> <td align="left" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Cough</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>38</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>18</paragraph> </td> </tr> <tr> <td align="left" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Headache</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>29</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>12</paragraph> </td> </tr> <tr> <td align="left" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Post lumbar puncture syndrome</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>29</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>6</paragraph> </td> </tr> <tr> <td align="left" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Arthralgia</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>25</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>6</paragraph> </td> </tr> <tr> <td align="left" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Oropharyngeal pain</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>21</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>0</paragraph> </td> </tr> <tr> <td align="left" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Dysphagia</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>17</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>6</paragraph> </td> </tr> </tbody> </table>

adverse reactions table

<table width="50%" cellspacing="0" cellpadding="0"> <caption>Table 3. Adverse Reactions in Patients with Alexander Disease that Occurred in &#x2265;10% of Patients Treated with ZANVASTRO and 10% Greater than Control</caption> <col width="33.33%" align="left" valign="middle"/> <col width="33.33%" align="left" valign="middle"/> <col width="33.33%" align="left" valign="middle"/> <thead> <tr styleCode="First Last"> <td rowspan="2" align="left" styleCode="Lrule Rrule Toprule Botrule"> <content styleCode="bold">Adverse Reaction</content> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <content styleCode="bold">ZANVASTRO 50 mg (N=24) % </content> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <content styleCode="bold">Control (N=17) % </content> </td> </tr> </thead> <tfoot> <tr styleCode="First Last"> <td colspan="3" align="left" styleCode="Lrule Rrule Toprule Botrule"/> </tr> </tfoot> <tbody> <tr> <td align="left" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Vomiting</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>50</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>29</paragraph> </td> </tr> <tr> <td align="left" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Back pain</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>50</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>18</paragraph> </td> </tr> <tr> <td align="left" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Cough</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>38</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>18</paragraph> </td> </tr> <tr> <td align="left" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Headache</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>29</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>12</paragraph> </td> </tr> <tr> <td align="left" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Post lumbar puncture syndrome</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>29</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>6</paragraph> </td> </tr> <tr> <td align="left" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Arthralgia</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>25</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>6</paragraph> </td> </tr> <tr> <td align="left" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Oropharyngeal pain</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>21</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>0</paragraph> </td> </tr> <tr> <td align="left" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Dysphagia</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>17</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>6</paragraph> </td> </tr> </tbody> </table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.